The road to tailored adjuvant chemotherapy for all four non-pancreatic periampullary cancers: An international multimethod cohort study.
Bas A UijterwijkDaniël H LemmersMichele GhidiniJohanna W WilminkAlberto ZaniboniGiuseppe Kito FusaiAlessandro ZerbiBas Groot KoerkampMisha LuyerPoya GhorbaniRoberto SalviaSteven WhiteBenedetto IelpoBrian K P GohUgo BoggiGeert KazemierMichael G HouseVasileios K MavroeidisBergthor BjörnssonMichele MazzolaMario SerradillaDimitris KorkolisAdnan AlseidiKeith J RobertsZahir SoonawallaPatrick PessauxWilliam E FisherSharnice KoekTara S KentMiljana VladimirovLouisa BolmNigel JamiesonRaffaele Dalla ValleJorg KleeffAlessandro MazzottaMiguel Angel Suarez MuñozSantiago Sánchez CabúsChad G BallAdam C BergerClarissa FerarriMarc G BesselinkMohammed Abu Hilalnull nullPublished in: British journal of cancer (2024)
Patients with resected AmpPB and dCCA appear to benefit from ACT. While the optimal ACT for AmpPB remains undetermined, it appears that dCCA shows the most favourable response to capecitabine monotherapy. Tailored adjuvant treatments are essential for enhancing prognosis across all four non-pancreatic periampullary adenocarcinomas.